Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 12/20 | 0.42 |
| ▸ | ACHE | P22303 | 12/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7997920 | 1.00 | HTT (0.45) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL7997918 | 1.00 | HTT (0.45) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL1710168 | 1.00 | HTT (0.45) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL6579165 | 0.96 | HTT (0.51) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL6579161 | 0.96 | HTT (0.51) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL6582144 | 0.94 | HTT (0.46) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL6582148 | 0.94 | HTT (0.46) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL27494189 | 0.94 | MEN1 (0.42) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL8000967 | 0.93 | HTT (0.44) | HTTHTR1AHTR2CHTR2ASLC6A4 | |
| SCHEMBL8000672 | 0.93 | HTT (0.44) | HTTHTR1AHTR2CHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782484-B2 | Method for producing a composite organic compound powder for medical use | ACTIVUS PHARMA CO., LTD. (JP) | 2017-10-10 | — | — | US | claimed |
| EP-2143423-B1 | METHOD FOR PRODUCING PULVERIZED ORGANIC COMPOUND PARTICLE | ACTIVUS PHARMA CO LTD (JP) | 2015-12-09 | — | — | EP | claimed |
| EP-2345426-B1 | COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE, METHOD FOR PRODUCING SAME AND SUSPENSION OF SAME | ACTIVUS PHARMA CO LTD (JP) | 2014-03-05 | — | — | EP | claimed |
| US-20140038931-A1 | METHOD FOR PRODUCING A COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE | ACTIVUS PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | claimed |
| US-20120237768-A1 | METHOD FOR PRODUCING PULVERIZED ORGANIC COMPOUND PARTICLE | ACTIVUS PHARMA CO., LTD. (JP) | 2012-09-20 | — | — | US | claimed |
| EP-2345426-A1 | COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE, METHOD FOR PRODUCING SAME AND SUSPENSION OF SAME | Activus Pharma Co., Ltd. (JP) | 2011-07-20 | — | — | EP | claimed |
| US-20110165259-A1 | COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE, METHOD FOR PRODUCING SAME AND SUSPENSION OF SAME | ACTIVUS PHARMA CO., LTD. (JP) | 2011-07-07 | — | — | US | claimed |
| US-20100016597-A1 | Method for producing pulverized organic compound particle | ACTIVUS PHARMA CO., LTD. (JP) | 2010-01-21 | — | — | US | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4665737-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4106876-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-0785190-B1 | Quinolinone derivative and antiallergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK & CHEMICALS (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-5942521-A | Quinolinone derivative and anti-allergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0933378-A1 | Quinolinone glycoside, production process, and anti-allergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0927718-A1 | Quinolinone derivative, method for preparing the same, and anti-allergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-07-07 | — | — | EP | disclosed |
| CN-1221738-A | Chinolinelone derivative, its prepn. method and antiabnormal reaction agent | DAINIPPON INK & CHEMICALS (JP) | 1999-07-07 | — | — | CN | disclosed |
| EP-0785190-A2 | Quinolinone derivative and antiallergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | HTT 2741/4885HTR1A 253/4885HTR2C 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.